-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Initiates Coverage On Latigo Biotherapeutics with Buy Rating, Announces Price Target of $50

Benzinga·09/01/2026 18:08:24
Listen to the news
Jefferies analyst Akash Tewari initiates coverage on Latigo Biotherapeutics (NASDAQ:LTGO) with a Buy rating and announces Price Target of $50.